{
    "clinical_study": {
        "@rank": "153246", 
        "brief_summary": {
            "textblock": "PRIMARY: To determine whether pentoxifylline changes the self-reported measures of quality\n      of life status, using measures of scores from double-blinded drug withdrawal and drug\n      restart periods.\n\n      SECONDARY: To measure the changes in monthly CD4 counts, fasting serum triglyceride levels,\n      and weight; to assess the safety of pentoxifylline in HIV-infected persons."
        }, 
        "brief_title": "An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Stable antiretroviral therapy.\n\n          -  Maintenance medication for opportunistic infection.\n\n        Patients must have:\n\n        HIV positivity.\n\n        NOTE:\n\n          -  Patients on an antiretroviral must have received it for at least 2 months and have no\n             currently perceived need to change or add to the regimen for the next 3 months.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Antiviral therapy (provided patient has been on such therapy for at least 2 months at\n             study entry and dose is stable).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Evidence of active opportunistic infection or malignancy requiring high-dose systemic\n             chemotherapy (only patients who are 30 days from a diagnosis of an opportunistic\n             infection and on appropriate maintenance medication are allowed).\n\n          -  Known significant intolerance or hypersensitivity to theophylline, theobromine\n             (chocolate), or caffeine, for reasons other than dyspepsia.\n\n          -  Inability to swallow tablets (gastric feeding tubes are allowed).\n\n          -  Active bleeding disorder or major bleeding source, including peptic ulcer or\n             gastritis.\n\n          -  Any symptoms suggestive of concurrent illness that are not attributable to overall\n             impairment by HIV or are not diagnosable based on the available evidence.\n\n          -  Not willing to comply with visit schedule and study procedures.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Concurrent use of the anticoagulant warfarin (Coumadin) and heparin.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Treatment with biologic response modifiers (e.g., interferon, interleukin) within 14\n             days prior to study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Major surgery within 30 days of study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002091", 
            "org_study_id": "118A", 
            "secondary_id": "91-02"
        }, 
        "intervention": {
            "intervention_name": "Pentoxifylline", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentoxifylline"
        }, 
        "keyword": [
            "Pentoxifylline", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brookline", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02445"
                }, 
                "name": "CRI of New England"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Cohen CJ, Dezube BJ, Day JM, Andradas V, Gagnon S, Rieker PP. The impact of pentoxifylline on quality of life. Int Conf AIDS. 1994 Aug 7-12;10(1):213 (abstract no PB0283)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002091"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Community Research Initiative of New England", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1993"
    }, 
    "geocoordinates": {
        "CRI of New England": "42.332 -71.121"
    }
}